4.23MMarket Cap-96P/E (TTM)
0.9900High0.9203Low100.63KVolume0.9300Open0.9249Pre Close96.31KTurnover4.78%Turnover RatioLossP/E (Static)4.38MShares16.320052wk High0.72P/B2.03MFloat Cap0.670052wk Low--Dividend TTM2.11MShs Float587200.0000Historical High--Div YieldTTM7.54%Amplitude0.6700Historical Low0.9570Avg Price1Lot Size
Biodexa Pharmaceuticals Stock Forum
They just might let this one go.... in one month after they beat it down again.
NEWS (late)
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washin...
pleased to announce that's its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.
News
No comment yet